Xeris Biopharma (NASDAQ:XERS) Reaches New 12-Month High – Time to Buy?

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $5.97 and last traded at $5.88, with a volume of 1014781 shares traded. The stock had previously closed at $5.81.

Analysts Set New Price Targets

Several research firms have recently weighed in on XERS. Jefferies Financial Group restated a “buy” rating and set a $6.00 price objective (up from $4.00) on shares of Xeris Biopharma in a research note on Wednesday, January 29th. HC Wainwright restated a “buy” rating and issued a $8.00 price objective (up previously from $6.60) on shares of Xeris Biopharma in a research note on Friday, March 7th. Leerink Partners lifted their target price on Xeris Biopharma from $5.00 to $6.00 and gave the stock an “outperform” rating in a research note on Friday, March 7th. Craig Hallum boosted their target price on Xeris Biopharma from $5.00 to $6.50 and gave the stock a “buy” rating in a report on Friday, March 7th. Finally, Piper Sandler reaffirmed a “neutral” rating and set a $4.00 price target (up previously from $3.00) on shares of Xeris Biopharma in a report on Friday, March 7th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $5.92.

Xeris Biopharma Stock Performance

The firm has a market capitalization of $915.94 million, a price-to-earnings ratio of -13.22 and a beta of 2.32. The company has a fifty day moving average of $3.88 and a two-hundred day moving average of $3.41.

Insider Activity at Xeris Biopharma

In related news, insider Beth Hecht sold 40,000 shares of the firm’s stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $5.43, for a total value of $217,200.00. Following the transaction, the insider now owns 1,353,510 shares in the company, valued at approximately $7,349,559.30. This trade represents a 2.87 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 4.56% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Xeris Biopharma

Several hedge funds have recently bought and sold shares of the company. NewEdge Advisors LLC bought a new stake in shares of Xeris Biopharma during the 4th quarter worth approximately $34,000. R Squared Ltd acquired a new position in Xeris Biopharma during the fourth quarter valued at approximately $42,000. Cibc World Markets Corp bought a new stake in Xeris Biopharma during the fourth quarter worth $44,000. Raymond James Financial Inc. acquired a new stake in shares of Xeris Biopharma in the 4th quarter valued at $45,000. Finally, Two Sigma Advisers LP bought a new position in shares of Xeris Biopharma in the 4th quarter valued at $47,000. 42.75% of the stock is owned by institutional investors.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.